Pregnancy Category C
- Antidiabetic agent
- Sulfonylurea, second generation
Stimulates insulin release from functioning beta cells in the pancreas; may improve binding between insulin and insulin receptors or increase the number of insulin receptors; more potent in effect than first-generation sulfonylureas.
Adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) Adjunct to insulin therapy in the stabilization of certain cases of insulin-dependent maturity-onset diabetes, reducing the insulin requirement and decreasing the chance of hypoglycemic reactions
Allergy to sulfonylureas; diabetes complicated by fever, severe infections, severe trauma, major surgery, ketosis, acidosis, coma (insulin is indicated in these conditions); Type I or juvenile diabetes, serious hepatic impairment, serious renal impairment, uremia, thyroid or endocrine impairment, glycosuria, hyperglycemia associated with primary renal disease; labor and delivery (if glipizide is used during pregnancy, discontinue drug at least 1 mo before delivery); lactation.
- GI: Anorexia, nausea, vomiting, epigastric discomfort, heartburn, diarrhea
- CV: Increased risk of cardiovascular mortality
- Hematologic: Leukopenia, thrombocytopenia, anemia
- Hypersensitivity: Allergic skin reactions, eczema, pruritus, erythema, urticaria, photosensitivity, fever, eosinophilia, jaundice
- Endocrine: Hypoglycemia
Are you a Doctor, Pharmacist, PA or a Nurse?
Join the Doctors Lounge online medical community
Editorial activities: Publish, peer review, edit online articles.
Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.